The predictive role of interim pet-ct in the treatment of hodgkin's lymphoma in children


Cite item

Full Text

Abstract

Propose - to estimate a role of the interim PET-CT using 2 methods: visual (Deauville scale) and semiquantitative (calculation of the standard uptake value - SUV). Methods. The results of PET-CT of 40 children with the Hodgkin's lymphoma (HL) received treatment since June, 2012 to September, 2016 were analysed. 37 patients - with newly diagnosed HL, 2 - with a recurrence and 1 - with a refractory HL entered into this group. Patients received therapy under protocols of treatment of HL, proved in the Institute of Pediatric Oncology and Hematology N.N.Blokhin National Medical Reseach Center of Oncology, depending on the status and a stage of a disease. In addition to the traditional study techniques (TRT) - ultrasonic investigation (ultrasonography), a computer tomography with i.v. gain (KT), the magnetic resonance imaging (MRI), to all patients was three times executed by PET-CT at various stages of therapy: before treatment, during therapy and after completion of the program chemotherapy. All studies were executed in alone PET center in NMIC of N.N.Blochin. Results. The sensitivity and specificity of the intermediate PET-CT were 100% and 73% while the sensitivity of TMI at the intermediate stage of treatment was 50%, specificity of 79%. Assessment 3 points on Deauville scale (a visual method) at a stage of the intermediate PET-research demonstrates sensitivity of a tumor to the carried-out chemotherapy and does not demand strengthening of intensity of treatment, even on condition of existence of a residual tumor. Conclusion. At the choice of a method of assessment of results of PET preference should be given to a visual method with use of the Deauville five-point scale.

About the authors

N S Kulichkina

N.N.Blokhin National Medical Reseach Center of Oncology of the Ministry of Health of the Russian Federation

Email: Natalia_kulichkina@maiLru
врач - детский онколог отд-ния химиотерапии гемобластозов НИИ детской онкологии и гематологии 115478, Russian Federation, Moscow, Kashirskoye sh., d. 23

E S Belyaeva

N.N.Blokhin National Medical Reseach Center of Oncology of the Ministry of Health of the Russian Federation

канд. мед. наук, врач - детский онколог отд-ния химиотерапии гемобластозов НИИ детской онкологии и гематологии 115478, Russian Federation, Moscow, Kashirskoye sh., d. 23

A V Popa

N.N.Blokhin National Medical Reseach Center of Oncology of the Ministry of Health of the Russian Federation

д-р мед. наук, проф., зав. отд-нием химиотерапии гемобластозов НИИ детской онкологии и гематологии 115478, Russian Federation, Moscow, Kashirskoye sh., d. 23

T T Valiev

N.N.Blokhin National Medical Reseach Center of Oncology of the Ministry of Health of the Russian Federation

д-р мед. наук, ст. науч. сотр. отд-ния химиотерапии гемобластозов НИИ детской онкологии и гематологии 115478, Russian Federation, Moscow, Kashirskoye sh., d. 23

A A Odzharova

N.N.Blokhin National Medical Reseach Center of Oncology of the Ministry of Health of the Russian Federation

канд. мед. наук, ст. науч. сотр. отд-ния позитронно-эмиссионной томографии НИИ детской онкологии и гематологии 115478, Russian Federation, Moscow, Kashirskoye sh., d. 23

G L Mentkevich

N.N.Blokhin National Medical Reseach Center of Oncology of the Ministry of Health of the Russian Federation

д-р мед. наук, проф., зам. дир. по лечебной и научной работе НИИ детской онкологии, зав. отд-нием химиотерапии и трансплантации костного мозга 115478, Russian Federation, Moscow, Kashirskoye sh., d. 23

References

  1. Cheson B.D, Fisher R.I, Barrington S.F. et al. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. J Clin Oncol 2014; 32:3059-67.
  2. Barrington S.F, Mikhaeel N.G, Kostakoglu L et al. Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014; 32:3 0-48-58.
  3. Engert A, Haverkamp H, Kobe C et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): A randomised, open-label,phase 3 non-inferiority trial Lancet 2012; 379:1791 -9.
  4. Thomson K.J, Kayani I, Ardeshna K. et al. A response-adjusted PETba- sed transplantation strategy in primary resistant and relapsed Hodgkin lymphoma. Leukemia 2013; 27:1419-22.
  5. Hutchings M. FDG-PET response-adapted therapy: is 18F-fluorodeo- xyglucose positron emission tomography a safe predictor for a change of therapy? Hematol Oncol Clin N Am 2014; 28 (1): 87-103.
  6. Radford J, Barringjon S, Cournell N. et al. Involved field radiotherapy vs no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma and a negative’ PET scan after 3 cycles ABVD: results of the UKNCRIRAPID trial. Blood2012; 120 (21): 54J.
  7. Беляева Е.С. Современные подходы к лечению детей с распространенными стадиями лимфомы Ходжкина. Автореф. дис.. канд. мед. наук. М., 2009.
  8. Gallamini A, Hutchings M., Rigacci L et al. Early interim 2-[18F]f uoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncology 2007; 25 (24): 3746-52.
  9. Oki Y, Chuang H, Chasen B. et al. The prognostic value of interim positron emission tomography scans in patients with classical Hodgkin lymphoma. Br Haematology 2014; 165 (1): 112-16.
  10. Furth C., Steffen Ingo G., Amthauer H. et al. Early and Late Therapy Response Assessment With 18-Fluorodeoxyglucose Positron Emission Tomography in Pediatric Hodgkin’s Lymphoma: Analysis of a Prospective Multicenter Trial] Clin Oncology 2009; 27 (26): 4385-91.
  11. Gallamini A, Barringtom S, Biggi A. et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauvillefive-point scale. Haematologica 2014; 99 (6): 1107-13.

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies